[Federal Register Volume 74, Number 39 (Monday, March 2, 2009)]
[Notices]
[Pages 9085-9086]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-4329]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Department of Defense, Assistant Secretary of Defense (Health 
Affairs).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (5 U.S.C., Appendix, as amended) and the Sunshine in the 
Government Act of 1976 (U.S.C. 552b, as amended) the Department of 
Defense announces the following Federal Advisory Committee Meeting of 
the Uniform Formulary Beneficiary Advisory Panel (hereafter referred to 
as the Panel).

DATES: March 26, 2009 from 8 a.m. to 4 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: LtCol Thomas Bacon, Designated Federal 
Officer, Uniform Formulary Beneficiary Advisory Panel, Skyline 5, Suite 
810, 5111 Leesburg Pike, Falls Church, VA 22041-3206; Telephone: (703) 
681-2890; Fax: (703) 681-1940; E-mail Address: <a href="/cdn-cgi/l/email-protection#6b090a1b190e1a1e0e181f182b1f060a4504180f45060207"><span class="__cf_email__" data-cfemail="73111203011602061600070033071e125d1c00175d1e1a1f">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director, TRICARE Management Activity, by 
the Pharmacy and Therapeutics (P&T) Committee regarding the Uniform 
Formulary.
    Meeting Agenda: Sign-In; Welcome and Opening Remarks; Public 
Citizen Comments; Scheduled Therapeutic Class Reviews--Long-acting beta 
agonists (LABAs); Inhaled corticosteroids (ICS), Combination long-
acting beta agonists/inhaled steroids (LABA/ICS Combos) and Designated 
newly approved drugs; Panel Discussions and Vote, and comments 
following each therapeutic class review.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 CFR 102-3.140 through 102-3.165, and the availability of space this 
meeting is open to the public. Seating is limited and will be provided 
only to the first 220 people signing in. All persons must sign in 
legibly.
    Administrative Work Meeting: Prior to the public meeting the Panel 
will conduct an Administrative Work Meeting from 7 a.m. to 7:50 a.m. to 
discuss administrative matters of the Panel. The Administrative Work 
Meeting will be held at the Naval Heritage Center Conference Room, 701 
Pennsylvania Avenue, NW., Washington DC 20004. Pursuant to 41 CFR 102-
3.160, the Administrative Work Meeting will be closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140, 
the public or interested organizations may submit written statements to 
the membership of the Panel at any time or in response to the stated 
agenda of a planned meeting. Written statements should be submitted to 
the Panel's Designated Federal Officer; the Designated Federal 
Officer's contact information can be obtained from the GSA's FACA 
Database--https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However,

[[Page 9086]]

if individual comments pertain to a specific topic being discussed at a 
planned meeting then these statements must be submitted no later than 
five (5) business days prior to the meeting in question. The Designated 
Federal Officer will review all submitted written statements and 
provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside one (1) hour for individual or interested groups to address 
the Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice, but if they still want to address the Panel then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
Designated Federal Officer will have a ``Sign Up Roster'' available at 
the Panel meeting, for registration on a first-come, first-serve basis. 
Those wishing to address the Panel will be given no more than five (5) 
minutes to present their comments, and at the end of the one (1) hour 
time period no further public comments will be accepted. Anyone who 
signs up to address the Panel but is unable to do so due to the time 
limitation may submit their comments in writing; however, they must 
understand that their written comments may not be reviewed prior to the 
Panel's deliberation. Accordingly, the Panel recommends that 
individuals and interested groups consider submitting written 
statements instead of addressing the Panel.

    February 24, 2009.
Patricia L. Toppings,
OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. E9-4329 Filed 2-27-09; 8:45 am]
BILLING CODE 5001-06-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>